SEC Company Response from Bionano Genomics, Inc. (BNGO) (CIK 0001411690) (BNGO) — Oct 16, 2019
Bionano Genomics, Inc. (BNGO) (CIK 0001411690)
Date: Oct. 16, 2019 · CIK: 0001411690 · Accession: 0001140361-19-018551
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233828
Letter
Oppenheimer & Co. Inc.
85 Broad Street
New York, New York 10004
October 16, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Bionano Genomics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-233828
Ladies and Gentlemen:
In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the several underwriters (the “Representative”), hereby joins in the request of Bionano Genomics, Inc. that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 8:00 a.m., Eastern Time, on Friday, October 18, 2019, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as the representative of the several underwriters, represents that the several underwriters have and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
OPPENHEIMER & CO. INC.
Show Raw Text
CORRESP
1
filename1.htm
Oppenheimer & Co. Inc.
85 Broad Street
New York, New York 10004
October 16, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Bionano Genomics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-233828
Ladies and Gentlemen:
In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the several underwriters (the “Representative”), hereby joins in the request of Bionano Genomics, Inc. that the
effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 8:00 a.m., Eastern Time, on Friday, October 18, 2019, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably
anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as the representative of the several underwriters, represents that the several underwriters have and will comply with the
requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
OPPENHEIMER & CO. INC.
As representative of the
several Underwriters
OPPENHEIMER & CO. INC.
By:
/s/ Peter Bennett
Name:
Peter Bennett
Title:
Managing Director, Head of Equity Capital Markets